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Mechanistic target of rapamycin inhibitorTuberous sclerosis complex (TSC) is a genetic disease inwhich overactivation ofmechanistic target of rapamycin
(mTOR) signaling leads to the growth of benign hamartomas in multiple organs, including the brain, and is
associated with a high rate of epilepsy and neurological deﬁcits. The mTOR inhibitor everolimus has been used
in the treatment of subependymal giant cell astrocytomas and renal angiomyolipomas in patients with TSC.
This article describes the case of a 13-year-old girl with TSC-associated epilepsy with refractory generalized
seizures who initiated treatment with everolimus and experienced subsequent improvement in several TSC
manifestations, including a reduction in seizure frequency from clusters of two or three daily to one every 2 to
4 weeks after 1.5 years of treatment.
© 2015 The Author. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
1.1. Etiology
Tuberous sclerosis complex (TSC) is an autosomal dominant
genetic disease [1]. Mutation of TSC1 and/or TSC2 genes results in
constitutive activation in mechanistic target of rapamycin (mTOR)
signaling; this triggers the growth of benign hamartomas in multiple
organs, including the kidneys, brain, heart, lungs, and skin [1]. Com-
mon manifestations of TSC include renal angiomyolipomas in 70% to
90% of patients; central nervous system manifestations, including
cortical tubers, subependymal nodules (SENs), and subependymal
giant cell astrocytomas (SEGAs), in up to 90% of patients; and skin
lesions in more than 90% of patients [1,2]. In the brain, disturbances
to normal cellular development and function can lead to epilepsy
and neurocognitive, behavioral, and psychiatric deﬁcits [2,3]. Epilep-
sy occurs in 60% to 90% of patients with TSC and is generally evident
within the ﬁrst year of life [1–3].chanistic target of rapamycin;
ndymal nodule; TSC, tuberous
y, 51NDunlap Street, Suite 335,
1 901 287 5325.
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Optimal management of TSC-associated seizures involves antiepilep-
tic drugs (AEDs). Vigabatrin is the recommended ﬁrst-line treatment for
infantile spasms, although its potential for retinal toxicity should be
taken into consideration [3,4]. Adrenocorticotropic hormone can also be
considered for infantile spasms if treatment with vigabatrin fails [3,4].
Depending on seizure type, conventional AEDs, such as lamotrigine,
topiramate, oxcarbazepine, and levetiracetam, may be effective [5–7].
Despite this, seizures are refractory to conventional AEDs in approximate-
ly one-third of patientswith TSCwith epilepsy [2,8]. Epilepsy surgerymay
be considered in appropriate candidates if medication-resistant seizures
persist and where a single or dominant seizure focus is identiﬁed [3,4].
Other treatment options include complete corpus callosotomy, vagus
nerve stimulation, or dietary therapy (e.g., ketogenic diet, low glycemic
index diet) [3,4]. There is a need, however, for new therapeutic options
for the treatment of epilepsy in TSC that improve patient quality of life
and cognitive function and provide seizure control [9]. This case study
illustrates the complexities of treatment in a patient with TSC-
associated epilepsy who also had SEGA, renal angiomyolipomas, and
retinal astrocytomas.
2. Case report
In May 2013, a female patient was referred to the Le Bonheur
Comprehensive Epilepsy Programand Tuberous Sclerosis Complex Cen-
ter of Excellence at Le Bonheur Children's Hospital in Memphis,
Tennessee, for diagnostic evaluation of intractable, symptomatic,he CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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time of initial observation and had a diagnosis of TSC and refractory sei-
zures. She was ﬁrst diagnosed with TSC when a cardiac rhabdomyoma
was discovered at the age of 2 months. There was no family history of
TSC. Infantile spasms were diagnosed at 11–12 months of age. In the
ﬁrst year after her seizures were diagnosed, she was treated with
clonazepam, phenobarbital, prednisone, topiramate, and divalproex so-
dium. Between the ages of 2 and 4 years, shewas seizure-free and off all
medications. However, she subsequently developed refractory seizures
that did not respond adequately to treatment with AEDs (carbamaze-
pine, phenobarbital, prednisone, clonazepam, divalproex sodium,
topiramate, levetiracetam, lamotrigine, clorazepate, oxcarbazepine,
vigabatrin, and ruﬁnamide) or vagus nerve stimulation.
Her seizure pattern included clusters of two to three seizures daily,
typically after waking in the morning. She had generalized tonic eleva-
tion or extension of both arms brieﬂy for a period of seconds. Between
seizures, she was usually confused, moving about, ﬁdgeting, and not
fully responsive. Developmentally, she could walk and was able to
speak but had mental impairment and autism spectrum disorder. She
underwent periodic nephrology monitoring with renal MRI every
6 months, cardiology evaluation with Holter every 2 years with occa-
sional echocardiogram, and ophthalmologic monitoring. Her treatment
included vagus nerve stimulation, with the ﬁrst vagus nerve stimulator
placement in 2006. The patient's parents believed that this helped re-
duce the frequency of generalized tonic seizures. At the time of our
ﬁrst visit, she was taking multiple AEDs, namely divalproex sodium,
lamotrigine, vigabatrin, and clobazam. She also received other medica-
tions, including folate, taurine, carnitine, multivitamin, laxative, and
Depo-Provera (since the start of menarche—with a slight decrease in
seizure frequency and more stable emotions).
A CT scan of the brain without contrast foundmultiple small, calciﬁed
SENs along the lateral ventricularmargins consistentwith TSC. Small, par-
tially calciﬁed bilateral SENs in the region of the intraventricular foramina
were also identiﬁed, and these were thought to be consistent with small
SEGAs. There was a small focus of subcortical white matter hypodensity
in the paramedian left frontal lobe near the vertex that was consistent
with cortical tubers. Small, irregularly calciﬁed lesions, which were most
likely small retinal astrocytomas, were apparent along the posterior mar-
gin of both globes near the optic nerve heads. Magnetic resonance imag-
ing of the brain and brain stem, with and without gadolinium contrast,
and functional MRI (fMRI) found parenchymal stigmata of TSC withmul-
tiple cortical tubers, white matter lesions, and SENs. Magnetic resonance
imaging ﬁndings were consistent with those from the CT. Multiple small
SENs were apparent along the margins of both lateral ventricles, and
some of them demonstrated mild enhancement and calciﬁcation
reﬂected by susceptibility effect. Small SENs were identiﬁed in the region
of the intraventricular foramina bilaterally, and there were SEGAs in the
region of the left and right foramen of Monro measuring up to 14 mm
and 7 mm, respectively. A subtle susceptibility effect was seen along the
posterior margins of both globes corresponding to the calciﬁed retinal
lesions seen on prior CT. The orbitswere otherwise unremarkable. During
fMRI, positive activation of the somatosensory cortex was observed for
the bilateral hands during activity, and bilateral paracentral lobule activa-
tion was observed during movement of the feet; anatomic localization of
primary sensorimotor corticeswas normal. In addition, positive activation
was identiﬁed in the leftmiddle temporal gyrus suggestive of left cerebral
hemispheric language lateralization.
Magnetic resonance imaging of the patient's abdomen,with andwith-
out gadolinium contrast, found multiple, bilateral, cortically based
angiomyolipomas. The largest lesion (3.4 cm×3.9 cm)waswithin the in-
ferior polar region of the left kidney. There were also multiple, small,
bilateral renal cysts. There was no evidence of hydronephrosis or
hydroureter, and the liver, gallbladder, spleen, adrenal glands, pancreas,
stomach, bowel, and descending abdominal aorta all appeared normal.
In addition to the imaging results, physical examination revealed a facial
plaque on the right side of her face below the eye extending down tothe cheek, hypopigmented macules, poliosis in the left frontal head re-
gion, prominent bilateral facial angioﬁbromas, and a periungual ﬁbroma
on the left hand at the fourth digit. Therewas no shagreen patch or dental
pitting.
Subsequent evaluation took place in the epilepsy monitoring unit
from May 6–10, 2013. Transcranial magnetic stimulation conﬁrmed
normal motor localization, and a dual-energy X-ray absorptiometry
(DEXA) scan was normal. Neuropsychologic testing results included a
Stanford–Binet Intelligence Scale composite score of 47 and a Peabody
Picture Vocabulary Test composite score of 22, both of which are consis-
tent with a developmental-level age of 3.5 years. The patient had a
marked decrease in ﬁne motor skills, more so on the left hand than
the right. Interictal single photon emission CT of the brain showedmul-
tiple areas of decreased blood ﬂow over temporal, parietal, frontal, and
occipital head regions. Magnetoencephalography showed epileptiform
dipoles over both frontal head regions, more on the right than on the
left. Prolonged video-EEG monitoring showed interictally that her
wake background EEG was normal, but that she had few normal sleep
patterns. Both during waking and in sleep, generalized epileptiform
discharges were observed. Three generalized tonic seizures were
observed lasting 37 to 49 s in duration, which progressed to complex
partial seizures with diffuse EEG onset. Genetic testing of TSC1 and
TSC2 showed that the patient had a TSC2mutation. Her VEGF-D serum
level was 503 pg/mL (normal is b600 pg/mL).
The patient's medications were altered as follows: divalproex
sodium was discontinued because her parents were not sure it was
beneﬁtting her; the dose of lamotrigine was increased to compen-
sate for the lack of pharmacokinetic interaction with discontinuation
of divalproex sodium; and vigabatrin and clobazam were continued.
The patient's vagus nerve stimulator was decreased from 3.0 to
2.5 mA, and her intermediate cycling paradigm was slightly altered.
Due to the nature of her seizures, focal resection was not an option;
corpus callosotomy was considered but deemed unnecessary at this
time. Based on the size of the largest angiomyolipoma in the patient's
left kidney and following a discussion with her family, it was decided
that she would beneﬁt from treatment with everolimus. Everolimus
was initiated at 5 mg/day, and serum levels were checked 4 weeks
later.
At a 1.5 year follow-up in the fall of 2014, thepatientwasmaintained
on everolimus 5 mg a day with a serum level of 6.9 ng/mL. She had had
no signiﬁcant side effects from everolimus and no cold sores. The large
angiomyolipoma in the left kidney decreased about 65% in size, and
no other new, large lesions were seen. The patient had no worsening
of her brain SEGA. Her retinal hamartomas were small and unchanged
in size. Her facial angioﬁbroma, which had been quite prominent and
red, was dramatically less red and no longer bled when she scratched
her face. Her other skin lesionswere unchanged. Her seizures decreased
from daily events to one every 2 to 4 weeks; these seizures were brief,
with essentially no postictal phase, and did not interfere with her
activities of daily living. Furthermore, none of the seizures now resulted
in falls. The patient's parents were happy with her treatment.
3. Discussion
Following the addition of the mTOR inhibitor everolimus, this
patient experienced improvements in several TSC manifestations
including epilepsy. The mTOR signaling pathway has been shown to
play a role in epilepsy [10–12]. Genetic mutations in TSC1 and/or TSC2
genes or brain injuries can result in hyperactivation of mTOR signaling
in TSC, thus, stimulating neuronal hyperexcitability and promoting
seizures [10,13–15]. Beneﬁcial effects of mTOR inhibition with
everolimus have been reported previously in patients with TSC and
epilepsy [9,16–19]. Everolimus treatment improved seizure control in
prospective phase I/II studies in patients with TSC [9] and in patients
with TSC-associated SEGA [16]. In one of these studies, Krueger et al.
examined 20 patients with conﬁrmed TSC with refractory epilepsy.
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treatment (weeks 13–16) with the 4-week period before everolimus
initiation (baseline, weeks 1–4) [9]. At the end of treatment, 12 patients
(60%) experienced reductions in seizure frequency of 50% or more,
three patients (15%) experienced reductions of 25% to 50%, and ﬁve
patients (25%) had reductions of less than 25% [9]. Overall, the median
seizure frequency decreased by 73% [9]. A few other small studies
have found similar results. In a single-center study involving seven
children and adolescents with TSC and refractory seizures treated with
an mTOR inhibitor (six with sirolimus and one with everolimus), all
but one of the patients experienced reductions in seizure frequency of
at least 25%, with most experiencing reductions between 50% to 90%
[17]. Additionally, seven patients with TSC and intractable epilepsy
received everolimus in a compassionate use trial, and four of these
patients had a reduction in seizure frequency ranging from 25% to
100% [18]. Cessation of seizures or a reduction in seizure frequency
was also reported in a small number of pediatric patients with TSC
who were treated with long-term everolimus [19]. However, more
data are necessary to elucidate the potential beneﬁts ofmTOR inhibition
on TSC-related seizures. A randomized, blinded, placebo controlled,
phase III trial is currently in progress to evaluate the effect of everolimus
on seizure activity in patients with TSC (clinicaltrials.gov identiﬁer
NCT01713946).
It should be noted that when patients receive everolimus con-
comitantly with AEDs, there is a need to potentially alter the dose
of everolimus based on the medication they are taking. For example,
a lower dose of everolimus would be started in a patient on a moder-
ate CYP3A4 inhibitor. In patients with TSC, the recommendation is to
reduce the everolimus dose by 50% [20]. In this case study, our pa-
tient was receiving lamotrigine, which does not inhibit any of the
CYP isoenzymes. Rather, lamotrigine is predominantly metabolized
by glucuronic acid conjugation [21]. It is also common in clinical
practice for patients receiving a CYP3A4 inducer (e.g., phenytoin,
phenobarbital, carbamazepine, primidone) to require a larger dose
of everolimus to achieve therapeutic serum levels. So if concomitant
use of strong inducers is required in patients with TSC, the dose of
everolimus should be doubled [20].
Although everolimus is not currently approved for the treatment of
refractory epilepsy in patients with TSC, it is approved for the treatment
of TSC-associated SEGA that requires intervention but cannot be
curatively resected and for the treatment of TSC-related renal
angiomyolipomas that do not require immediate surgery [20]. Several
clinical trials have reported the beneﬁts of oral everolimus in reducing
SEGA and renal angiomyolipoma volume and in reducing the appear-
ance of skin lesions in patients with TSC [16,22–25]. Systemic treatment
with mTOR inhibitors targets the underlying pathophysiology of TSC
and has the potential for concurrent improvement of multiple lesions
in a wide variety of tissues. Concurrent reduction in angiomyolipoma
and SEGA volumes, seizure frequency, and skin lesions have been
demonstrated previously with everolimus administration in patients
with TSC [22,23,26–29].
4. Conclusion
Wepresent the case of an adolescent girlwithmultiple diseaseman-
ifestations of TSC and refractory epilepsy who beneﬁtted from treat-
ment with everolimus as demonstrated by shrinkage of renal
angiomyolipoma, dramatic improvement in facial angioﬁbromas, and
reduction in seizure frequency.
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